Lectin-mediated Drug Targeting: Preparation, Binding Characteristics, and Antiproliferative Activity of Wheat Germ Agglutinin Conjugated Doxorubicin on Caco-2 Cells

Overview

Journal Pharm Res

Specialties Pharmacology
Pharmacy

Date 1998 Aug 4

PMID 9688056

Citations 9

Authors

M Wirth

A Fuchs

M Wolf

B Ertl

F Gabor

Affiliations

Soon will be listed here.

Abstract

Purpose: To investigate the usefulness of wheat germ agglutinin as a targeting carrier protein for an acid-labile chemotherapeutic prodrug directed against colon carcinoma cells in vitro.

Methods: Cis-aconityl-linked doxorubicin-wheat germ agglutinin was prepared by a two step procedure and the conjugate-binding capacity of target- and non-target cells was assayed by flow cytometry. The antiproliferative activity of the prodrug on Caco-2 and MOLT-4 cells was determined by the XTT- and BrdU-test and compared with that of the parent drug and the lectin alone.

Results: At pH 4.0, about 50% of the conjugated doxorubicin were released within 24 h from the water soluble prodrug exhibiting a conjugation number of 24 (mol doxorubicin/mol WGA). The prodrug-binding capacity of colon carcinoma cells exceeded that of human colonocytes and lymphoblastic MOLT-4 cells 4.5-fold. Additionally, the antiproliferative effect of the conjugate on Caco-2 cells was 39% as opposed to 5% in case of MOLT-4 cells. As the unmodified carrier protein inhibited or stimulated Caco-2 cell growth in a concentration-dependent manner, the cytostatic activity of the conjugate was determined at WGA concentrations without an effect on cell-proliferation. Considering 50% release of conjugated drug at the most, the prodrug yielded 160% of the cytostatic activity of free doxorubicin.

Conclusions: WGA-prodrug targeting offers new perspectives for site-specific, cytoinvading drug delivery in colon cancer chemotherapy.

Citing Articles

Carbohydrate-Protein Interactions: Advances and Challenges.

Zhang S, Chen K, Zou X Commun Inf Syst. 2021; 21(1):147-163.

PMID: 34366717 PMC: 8336717. DOI: 10.4310/cis.2021.v21.n1.a7.

Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come.

Yingchoncharoen P, Kalinowski D, Richardson D Pharmacol Rev. 2016; 68(3):701-87.

PMID: 27363439 PMC: 4931871. DOI: 10.1124/pr.115.012070.

Biomimickry of UPEC Cytoinvasion: A Novel Concept for Improved Drug Delivery in UTI.

Pichl C, Dunkl B, Brauner B, Gabor F, Wirth M, Neutsch L Pathogens. 2016; 5(1).

PMID: 26861401 PMC: 4810137. DOI: 10.3390/pathogens5010016.

Intracellular delivery of nanoparticles of an antiasthmatic drug.

Surti N, Naik S, Bagchi T, Dwarkanath B, Misra A AAPS PharmSciTech. 2008; 9(1):217-23.

PMID: 18446484 PMC: 2976900. DOI: 10.1208/s12249-008-9036-x.

Analysis of unconventional approaches for the rapid detection of surface lectin binding ligands on human cell lines.

Welty L, Heinrich E, Garcia K, Banner L, Summers M, Baresi L Acta Histochem. 2006; 107(6):411-20.

PMID: 16414103 PMC: 1857331. DOI: 10.1016/j.acthis.2005.10.005.

References

Kronis K, CARVER J . Specificity of isolectins of wheat germ agglutinin for sialyloligosaccharides: a 360-MHz proton nuclear magnetic resonance binding study. Biochemistry. 1982; 21(13):3050-7. DOI: 10.1021/bi00256a003. View

Ramanathan M . Flow cytometry applications in pharmacodynamics and drug delivery. Pharm Res. 1997; 14(9):1106-14. DOI: 10.1023/a:1012178001348. View

Zeng F, Benguria A, Kafert S, Andre S, Gabius H, Villalobo A . Differential response of the epidermal growth factor receptor tyrosine kinase activity to several plant and mammalian lectins. Mol Cell Biochem. 1995; 142(2):117-24. DOI: 10.1007/BF00928932. View

Duncan R, Connors T, Meada H . Drug targeting in cancer therapy: the magic bullet, what next?. J Drug Target. 1996; 3(5):317-9. DOI: 10.3109/10611869608996823. View

Kreuter J . Nanoparticulate systems in drug delivery and targeting. J Drug Target. 1995; 3(3):171-3. DOI: 10.3109/10611869509015940. View

Dillman R, Johnson D, Shawler D, Koziol J . Superiority of an acid-labile daunorubicin-monoclonal antibody immunoconjugate compared to free drug. Cancer Res. 1988; 48(21):6097-102. View

Singhal A, Hakomori S . Molecular changes in carbohydrate antigens associated with cancer. Bioessays. 1990; 12(5):223-30. DOI: 10.1002/bies.950120506. View

Kawamoto T, Sato J, Le A, Polikoff J, Sato G, Mendelsohn J . Growth stimulation of A431 cells by epidermal growth factor: identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody. Proc Natl Acad Sci U S A. 1983; 80(5):1337-41. PMC: 393592. DOI: 10.1073/pnas.80.5.1337. View

Thrush G, Lark L, Clinchy B, Vitetta E . Immunotoxins: an update. Annu Rev Immunol. 1996; 14:49-71. DOI: 10.1146/annurev.immunol.14.1.49. View

10.

Ryder S, Smith J, Rhodes E, Parker N, Rhodes J . Proliferative responses of HT29 and Caco2 human colorectal cancer cells to a panel of lectins. Gastroenterology. 1994; 106(1):85-93. DOI: 10.1016/s0016-5085(94)94527-6. View

11.

Shen W, RYSER H . cis-Aconityl spacer between daunomycin and macromolecular carriers: a model of pH-sensitive linkage releasing drug from a lysosomotropic conjugate. Biochem Biophys Res Commun. 1981; 102(3):1048-54. DOI: 10.1016/0006-291x(81)91644-2. View

12.

Sharon N, Lis H . Lectins: cell-agglutinating and sugar-specific proteins. Science. 1972; 177(4053):949-59. DOI: 10.1126/science.177.4053.949. View

13.

Wilchek M, Miron T, Kohn J . Affinity chromatography. Methods Enzymol. 1984; 104:3-55. DOI: 10.1016/s0076-6879(84)04082-9. View

14.

Yin W, Cheng P . Lectin conjugate-directed gene transfer to airway epithelial cells. Biochem Biophys Res Commun. 1994; 205(1):826-33. DOI: 10.1006/bbrc.1994.2739. View

15.

Pusztai A, Ewen S, Grant G, Brown D, Stewart J, Peumans W . Antinutritive effects of wheat-germ agglutinin and other N-acetylglucosamine-specific lectins. Br J Nutr. 1993; 70(1):313-21. DOI: 10.1079/bjn19930124. View

16.

Yang H, Reisfeld R . Doxorubicin conjugated with a monoclonal antibody directed to a human melanoma-associated proteoglycan suppresses the growth of established tumor xenografts in nude mice. Proc Natl Acad Sci U S A. 1988; 85(4):1189-93. PMC: 279732. DOI: 10.1073/pnas.85.4.1189. View

17.

Gabor F, Haberl I, Wirth M, Richter K, Theyer G, Baumgartner G . In vitro antitumor activity of MIC2 protein-doxorubicin conjugates. Int J Oncol. 2011; 9(3):527-31. DOI: 10.3892/ijo.9.3.527. View